Ginkgo Bioworks (DNA) Issues 2021 Revenue Guidance and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review
January 12, 2022 7:00 AM ESTBOSTON, Jan. 12, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December 31, 2021. Among the results, Ginkgo highlighted that it expects to meet or exceed its key 2021 full year targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings based on its preliminary unaudited estimates. The results, along with a broader business review, will be featured in a presentation today at the 40th Annual J.P. Morgan Healthcare Conference.
... More
